FDA Grants First-Ever Approval for DIPG Treatment as Family Advocacy Fuels Research Momentum
核心洞察
The FDA granted accelerated approval to dordaviprone (Modeyso (搜索)) in August 2025 for recurrent H3 K27M (搜索)-mutant diffuse midline glioma (搜索), the first-ever approved medication for this brain cancer type.
DIPG accounts for 75% to 80% of pediatric brainstem tumors, with 150 to 300 U.S. children diagnosed annually and fewer than 10% surviving two years.
UW-Madison researcher Owen Tamplin uses transparent zebrafish models to study DIPG tumor formation and screen drug combinations, reporting a promising compound called P2.
The death of a six-year-old Oak Park boy from diffuse intrinsic pontine glioma (搜索) (DIPG) has become a catalyst for both a national advocacy movement and a landmark regulatory milestone. In August 2025, the FDA granted accelerated approval to dordaviprone, marketed as Modeyso (搜索), for recurrent H3 K27M (搜索)-mutant diffuse midline glioma (搜索), marking the first-ever FDA-approved medication for this type of brain cancer, according to Jazz Pharmaceuticals. The approval reflects a broader shift in how the disease is understood and treated, moving diagnosis away from tumor location and toward genetic mutation.
A Rare and Deadly Childhood Cancer
DIPG is an aggressive brainstem cancer that is almost always fatal. It accounts for 75% to 80% of all pediatric brainstem tumors, with an estimated 150 to 300 children diagnosed annually in the United States at a median age of 6 to 7, according to DIPG.org. Surgical removal is generally impossible because the cancer cells diffusely infiltrate the pons, the brainstem structure that controls breathing, heart rate, and swallowing, per St. Jude Children's Research Hospital.
The prognosis remains grim. The median survival time for DIPG after diagnosis is 9 to 12 months, with fewer than 10% of patients surviving two years and roughly 2% surviving five years, according to the Team Jack Foundation. Standard treatment includes 30 rounds of radiation, but for many patients the radiation does not work and fails to relieve symptoms as intended.
A Molecular Reclassification and a First Approval
The therapeutic landscape shifted in 2016, when the World Health Organization reclassified brainstem tumors historically known as DIPG into a broader molecular category called diffuse midline glioma (搜索), H3 K27M (搜索)-mutant, moving diagnosis away from tumor location and toward genetic mutation, per NORD. This reclassification set the stage for targeted therapies.
Dordaviprone works by targeting cancer cell mitochondria and dopamine receptors, according to Jazz Pharmaceuticals. Its accelerated approval for recurrent H3 K27M (搜索)-mutant diffuse midline glioma (搜索) represents the first FDA-approved medication for this brain cancer type, a milestone that underscores the impact of sustained scientific and grassroots pressure.
Zebrafish Models Advance Drug Discovery
At the University of Wisconsin-Madison, researcher Owen Tamplin has turned to an unlikely model organism to study DIPG: the zebrafish. Tamplin, who previously studied blood stem cells in leukemia treatment, shifted his focus after learning that Owen Petrzelka—his daughter's pre-K classmate in Oak Park—had been diagnosed with the disease.
"Then I moved my lab to UW-Madison in 2020. That was the same year we learned Owen had gotten sick," Tamplin said. "That was what really led to my journey studying this particular brain cancer; getting to know Owen and the struggles he went through."
Zebrafish offer distinct advantages for cancer research. "It turns out they're really similar to us in a lot of ways," Tamplin explained. "Brain development is similar, so are regions of brains. The tumor cells behave very similarly to the way they do in humans." Because zebrafish are transparent, researchers can observe tumor formation directly. "We can look at development under the microscope, see where, when these tumors start to form. We can think about how to treat them early on," he said.
The research has produced encouraging results. Tamplin reported finding a drug, P2, that could work on blood stem cells in fish and also improves transplantations for human patients in clinical trials, describing the development as "promising." The work is now focused on combination approaches. "We're at a stage now, trying to find drugs we can treat the fish with it and see if they can slow tumors," Tamplin said. "Something that's interesting now in clinic is not one treatment, but possibly combinations of treatments, like you get a chemo cocktail."
Advocacy Confronts a Funding Gap
The scientific progress has been propelled by families who have lost children to the disease. Amanda Shaker, Owen Petrzelka's mother, has framed her advocacy in blunt terms: people with smaller-population diseases still matter, and rare diseases should not mean forgotten diseases. Her argument aligns with federal funding data showing that historically only about 4% of total federal cancer research funding from the National Cancer Institute goes to all pediatric cancers combined, leaving adult cancers with the remaining 96%, according to a report from the American Association for Cancer Research.
What began as a virtual 5K sponsored by the ChadTough Defeat DIPG Foundation (搜索) has grown into an annual block party drawing more than 1,000 people each year. The ChadTough Defeat DIPG Foundation was founded by Tammi and Jason Carr after they lost their five-year-old son, Chad, to DIPG in 2015, and has grown into a national nonprofit funding clinical trials and pediatric brain tumor research. By September 2025, the event, known as RunTough for Team Owen, had raised $111,547 for pediatric brain cancer research.
For Tamplin, the work remains deeply personal. "I would love to be able to give her good news, to know that we are producing something in the lab to make a contribution," he said. "I got into research hoping to make a difference. Sometimes it can take many, many years. Despite the challenges, it's a very rewarding path."